SGLT2 inhibitor treatment remained independently associated with a lower risk of new-onset atrial fibrillation (adjusted β = −0.249, 95% CI: −0.338 to −0.161, p < 0.0001). Here, SLC5A2 is linked to atrial fibrillation.